APA aipamena

Fietz, S., Zarbl, R., Niebel, D., Posch, C., Brossart, P., Gielen, G. H., . . . Dietrich, D. (2020). CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). Cancer Immunol Immunother.

Chicago Style aipamena

Fietz, Simon, et al. "CTLA4 Promoter Methylation Predicts Response and Progression-free Survival in Stage IV Melanoma Treated With Anti-CTLA-4 Immunotherapy (ipilimumab)." Cancer Immunol Immunother 2020.

MLA aipamena

Fietz, Simon, et al. "CTLA4 Promoter Methylation Predicts Response and Progression-free Survival in Stage IV Melanoma Treated With Anti-CTLA-4 Immunotherapy (ipilimumab)." Cancer Immunol Immunother 2020.